Acticor Biotech (France) Probability of Future Stock Price Finishing Under 0.34
| ALACT Stock | EUR 0.29 0.02 7.41% |
Acticor |
Acticor Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Acticor Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Acticor Biotech SAS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Acticor Biotech SAS is way too risky over 90 days horizon | |
| Acticor Biotech SAS has some characteristics of a very speculative penny stock | |
| Acticor Biotech SAS appears to be risky and price may revert if volatility continues | |
| Acticor Biotech SAS has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (12.61 M) with profit before overhead, payroll, taxes, and interest of 320.18 K. | |
| Acticor Biotech SAS has accumulated about 571.18 K in cash with (13.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17. |
Acticor Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Acticor Stock often depends not only on the future outlook of the current and potential Acticor Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Acticor Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 107.5 M | |
| Cash And Short Term Investments | 11.3 M |
Acticor Biotech Technical Analysis
Acticor Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. Acticor Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Acticor Biotech SAS. In general, you should focus on analyzing Acticor Stock price patterns and their correlations with different microeconomic environments and drivers.
Acticor Biotech Predictive Forecast Models
Acticor Biotech's time-series forecasting models is one of many Acticor Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Acticor Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Acticor Biotech SAS
Checking the ongoing alerts about Acticor Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Acticor Biotech SAS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Acticor Biotech SAS is way too risky over 90 days horizon | |
| Acticor Biotech SAS has some characteristics of a very speculative penny stock | |
| Acticor Biotech SAS appears to be risky and price may revert if volatility continues | |
| Acticor Biotech SAS has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (12.61 M) with profit before overhead, payroll, taxes, and interest of 320.18 K. | |
| Acticor Biotech SAS has accumulated about 571.18 K in cash with (13.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17. |
Additional Tools for Acticor Stock Analysis
When running Acticor Biotech's price analysis, check to measure Acticor Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acticor Biotech is operating at the current time. Most of Acticor Biotech's value examination focuses on studying past and present price action to predict the probability of Acticor Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acticor Biotech's price. Additionally, you may evaluate how the addition of Acticor Biotech to your portfolios can decrease your overall portfolio volatility.